Jump to content

Sunovion: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Tags: Reverted Mobile edit Mobile web edit
abetlane
Tags: Reverted Visual edit
Line 12: Line 12:
| location = [[Marlborough, Massachusetts|Marlborough]], [[Massachusetts]], [[United States]]
| location = [[Marlborough, Massachusetts|Marlborough]], [[Massachusetts]], [[United States]]
}}
}}
On July 1, 2023, '''Sunovion Pharmaceuticals Inc.''' became part of Sumitomo Pharma America, Inc.,<ref>{{Cite web |date=2023-07-10 |title=Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities |url=https://finance.yahoo.com/news/sumitomo-pharma-america-launches-combined-113000065.html |access-date=2023-07-13 |website=Yahoo Finance |language=en-US}}</ref> a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.
'''Sunovion Pharmaceuticals Inc.''' (former [[Nasdaq|NASDAQ]]: ''SEPR''), known until October 12, 2010 as '''Sepracor, Inc.''' prior to its acquisition by [[Sumitomo Pharma]] <ref name="PR">[http://www.sunovion.com/news/pressReleases/20101012.pdf Company press release]</ref> is an American [[pharmaceutical company]] founded in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. It was originally located in [[Princeton, New Jersey|Princeton]], [[New Jersey]] and then re-located to [[Marlborough, Massachusetts|Marlborough]], [[Massachusetts]].<ref>[https://finance.yahoo.com/q/pr?s=sepr SEPR: Profile for SEPRACOR INC - Yahoo! Finance]</ref> In addition to its headquarters in [[Marlborough, Massachusetts|Marlborough]], Sunovion has locations in [[Mississauga|Mississauga, Ontario]], and [[Teaneck, New Jersey]].

Sunovion was founded as Sepracor, Inc. in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. Sepracor completed its initial public offering in 1991, trading on NASDAQ under the ticker SEPR. On October 12, 1010, Sepracor, Inc. was acquired by and became a standalone subsidiary of Sumitomo Pharma of Japan (then known as Sumitomo Dainippon Pharma). In April 2023, Sumitomo Pharma announced the combination of its U.S. subsidiaries, including Sunovion, to form Sumitomo Pharma America (SMPA)<ref>{{Cite web |last=Armstrong |first=Annalee |date=Apr 3, 2023 |title=Sumitomo Pharma tidies up 7 units into one combined US entity in spring cleaning |url=https://www.fiercebiotech.com/biotech/sumitomo-pharma-tidies-7-units-one-combined-us-entity-spring-cleaning |access-date=July 13, 2023 |website=Fierce Biotech}}</ref>.


==Company history==
==Company history==
The company's initial focus was on the separation and purification of [[Isomer|isomers]] and active [[metabolite]]s. Sepracor completed its initial public offering in 1991 at a market cap of $160M, behind a strategy of presenting larger pharmaceuticals with patented, purified active ingredients for expiring products. In 1993, [[Marion Merrell Dow]], now a part of [[Sanofi]], partnered with Sepracor to develop a purified version of its antihistamine, [[Seldane]], after the latter was required to carry a warning about potentially fatal cardiac arrhythmia. This purified compound would later be marketed as [[Fexofenadine|Allegra]], but Sepracor would not profit significantly from its launch, a result of less-than favorable partnership terms.
Sepracor completed its initial public offering in 1991 at a market cap of $160M. The company's initial focus was on the separation and purification of [[Isomer|isomers]] and active [[metabolite]]s. The strategy was to present larger pharmaceuticals with patented, purified active ingredients for expiring products. In 1993, [[Marion Merrell Dow]], now a part of [[Sanofi]], partnered with Sepracor to develop a purified version of its antihistamine, [[Seldane]], after the latter was required to carry a warning about potentially fatal cardiac arrhythmia. This purified compound would later be marketed as [[Fexofenadine|Allegra]], but Sepracor would not profit significantly from its launch, a result of less-than favorable partnership terms.


Sepracor's subsequent products were focused on the treatment of [[Central nervous system disease|central nervous system]] and [[Respiratory disease|respiratory disorders]], under the direction of Gunnar Aberg and John McCullough. The primary source of its revenue in the late 1990s - early 2000s was the approximately $600 million annually from its [[Xopenex]] franchise of drugs. The insomnia drug [[Lunesta]] (eszopiclone) was approved by the [[Food and Drug Administration (United States)|US Food and Drug Administration]] (FDA) in December 2004 and launched in April 2005. In 2006, the FDA approved Sepracor's drug [[Brovana]] to treat [[chronic obstructive pulmonary disease|chronic obstructive pulmonary disease (COPD)]].<ref>{{Cite web|url=https://www.biospace.com/article/fda-approves-sepracor-inc-s-brovana-tm-arformoterol-tartrate-inhalation-solution-for-chronic-obstructive-pulmonary-disease-/|title=FDA Approves Sepracor, Inc.'s BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution For Chronic Obstructive Pulmonary Disease|website=BioSpace|language=en-US|access-date=2020-02-10}}</ref>
Sepracor's subsequent products were focused on the treatment of [[Central nervous system disease|central nervous system]] and [[Respiratory disease|respiratory disorders]], under the direction of Gunnar Aberg and John McCullough. The primary source of its revenue in the late 1990s - early 2000s was the approximately $600 million annually from its [[Xopenex]] franchise of drugs. The insomnia drug [[Lunesta]] (eszopiclone) was approved by the [[Food and Drug Administration (United States)|US Food and Drug Administration]] (FDA) in December 2004 and launched in April 2005. In 2006, the FDA approved Sepracor's drug [[Brovana]] to treat [[chronic obstructive pulmonary disease|chronic obstructive pulmonary disease (COPD)]].<ref>{{Cite web|url=https://www.biospace.com/article/fda-approves-sepracor-inc-s-brovana-tm-arformoterol-tartrate-inhalation-solution-for-chronic-obstructive-pulmonary-disease-/|title=FDA Approves Sepracor, Inc.'s BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution For Chronic Obstructive Pulmonary Disease|website=BioSpace|language=en-US|access-date=2020-02-10}}</ref>


⚫
In 2008, [[Bial]] agreed with the company to produce and market its antiepileptic drug [[eslicarbazepine acetate|Aptiom]] at Sepracor's facilities and supervised by Bial.<ref>{{cite web|url=http://www.bial.com/noticias/detalhes.php?id=163|title=Bial - caring for your health|publisher=}}</ref> Aptiom subsequently received FDA approval in 2013 to treat [[Focal seizure|partial onset seizures]].
⚫
===Acquisition by Sumitomo Dainippon Pharma===
⚫
Sepracor was acquired by then-Sumitomo Dainippon Pharma in 2010 for $2.6B.<ref name="PR">[http://www.sunovion.com/news/pressReleases/20101012.pdf Company press release]</ref> Sepracor would become an indirect, wholly owned subsidiary of [[Dainippon Sumitomo Pharma]] and renamed to Sunovion.


⚫
In 2010, [[Latuda]], an atypical antipsychotic drug, received FDA approval for the treatment of [[schizophrenia]] and in 2013, received a secondary approval for the treatment of [[bipolar depression|depressive episodes]] associated with [[Bipolar I Disorder]].
===Sunovion's History===


⚫
===Acquisition by Sumitomo Dainippon Pharma===
⚫
In 2008, [[Bial]] agreed with then-Sepracor to produce and market its antiepileptic [[eslicarbazepine acetate|Aptiom]] at Sepracor's facilities and supervised by Bial.<ref>{{cite web|url=http://www.bial.com/noticias/detalhes.php?id=163|title=Bial - caring for your health|publisher=}}</ref> Aptiom subsequently received FDA approval in 2013 to treat [[Focal seizure|partial onset seizures]].
⚫
Sepracor was acquired by then-Sumitomo Dainippon Pharma in 2010 for $2.6B.<ref name="PR">[http://www.sunovion.com/news/pressReleases/20101012.pdf Company press release]</ref> Sepracor would become an indirect, wholly owned subsidiary of [[Dainippon Sumitomo Pharma]] and renamed to Sunovion.


===Combination to form Sumitomo Pharma America===
⚫
In 2010, [[Latuda]], an atypical antipsychotic, received FDA approval for the treatment of [[schizophrenia]] and in 2013, received a secondary approval for the treatment of [[bipolar depression|depressive episodes]] associated with [[Bipolar I Disorder]].
On April 3, 2023, Sunovion Pharmaceuticals, an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with Sumitomo Pharma’s other affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. (SMPA), effective July 1, 2023<ref>{{Cite web |title=Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America |url=https://www.businesswire.com/news/home/20230402005060/en/Sumitomo-Pharma-Subsidiary-Companies-in-the-U.S.-Including-Sunovion-to-Combine-and-Form-Sumitomo-Pharma-America |access-date=2023-07-13 |website=BUSINESS WIRE |language=en-US}}</ref>.


==Products Under Development==
==Products Under Development==

Revision as of 17:59, 13 July 2023

Sunovion Pharmaceuticals Inc.
Company typeSubsidiary
IndustryPharmaceuticals
Founded1984
HeadquartersMarlborough, Massachusetts, United States
Key people
Antony Loebel (President and CEO)
ProductsLatuda
Aptiom
Kynmobi
Lonhala Magnair
Lunesta
ParentSumitomo Pharma
Websitehttp://www.sunovion.com

On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc.,[1] a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.

Sunovion was founded as Sepracor, Inc. in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. Sepracor completed its initial public offering in 1991, trading on NASDAQ under the ticker SEPR. On October 12, 1010, Sepracor, Inc. was acquired by and became a standalone subsidiary of Sumitomo Pharma of Japan (then known as Sumitomo Dainippon Pharma). In April 2023, Sumitomo Pharma announced the combination of its U.S. subsidiaries, including Sunovion, to form Sumitomo Pharma America (SMPA)[2].

Company history

Sepracor completed its initial public offering in 1991 at a market cap of $160M. The company's initial focus was on the separation and purification of isomers and active metabolites. The strategy was to present larger pharmaceuticals with patented, purified active ingredients for expiring products. In 1993, Marion Merrell Dow, now a part of Sanofi, partnered with Sepracor to develop a purified version of its antihistamine, Seldane, after the latter was required to carry a warning about potentially fatal cardiac arrhythmia. This purified compound would later be marketed as Allegra, but Sepracor would not profit significantly from its launch, a result of less-than favorable partnership terms.

Sepracor's subsequent products were focused on the treatment of central nervous system and respiratory disorders, under the direction of Gunnar Aberg and John McCullough. The primary source of its revenue in the late 1990s - early 2000s was the approximately $600 million annually from its Xopenex franchise of drugs. The insomnia drug Lunesta (eszopiclone) was approved by the US Food and Drug Administration (FDA) in December 2004 and launched in April 2005. In 2006, the FDA approved Sepracor's drug Brovana to treat chronic obstructive pulmonary disease (COPD).[3]

In 2008, Bial agreed with the company to produce and market its antiepileptic drug Aptiom at Sepracor's facilities and supervised by Bial.[4] Aptiom subsequently received FDA approval in 2013 to treat partial onset seizures.

In 2010, Latuda, an atypical antipsychotic drug, received FDA approval for the treatment of schizophrenia and in 2013, received a secondary approval for the treatment of depressive episodes associated with Bipolar I Disorder.

Acquisition by Sumitomo Dainippon Pharma

Sepracor was acquired by then-Sumitomo Dainippon Pharma in 2010 for $2.6B.[5] Sepracor would become an indirect, wholly owned subsidiary of Dainippon Sumitomo Pharma and renamed to Sunovion.

Combination to form Sumitomo Pharma America

On April 3, 2023, Sunovion Pharmaceuticals, an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with Sumitomo Pharma’s other affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. (SMPA), effective July 1, 2023[6].

Products Under Development

List of mergers and acquisitions

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

References

  1. ^ "Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities". Yahoo Finance. 2023-07-10. Retrieved 2023-07-13.
  2. ^ Armstrong, Annalee (Apr 3, 2023). "Sumitomo Pharma tidies up 7 units into one combined US entity in spring cleaning". Fierce Biotech. Retrieved July 13, 2023.
  3. ^ "FDA Approves Sepracor, Inc.'s BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution For Chronic Obstructive Pulmonary Disease". BioSpace. Retrieved 2020-02-10.
  4. ^ "Bial - caring for your health".
  5. ^ Company press release
  6. ^ "Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America". BUSINESS WIRE. Retrieved 2023-07-13.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sunovion&oldid=1165207117"